CLINICAL TRIALS PROFILE FOR RIOCIGUAT
✉ Email this page to a colleague
All Clinical Trials for RIOCIGUAT
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00855660 ↗ | Effect of Riociguat on Bone Metabolism | Completed | Bayer | Phase 1 | 2009-03-01 | Investigation of the effect of Riociguat, administered as 2.5 mg IR-tablets TID over 14 days, on bone metabolism. |
NCT01014247 ↗ | Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation | Completed | Bayer | Phase 1 | 2009-11-01 | The aim of this study is to investigate the effect of moxifloxacin on the QT interval in order to gain information on the validity of results that will be collected during another clinical study testing riociguat in patients with pulmonary arterial hypertension (PATENT-1 study). |
NCT01065051 ↗ | Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics | Terminated | Bayer | Phase 2 | 2010-11-01 | The aim of this study is to assess whether oral Riociguat affects the left ventricular contractility and relaxation in patients with pulmonary hypertension associated with left ventricular systolic dysfunction |
NCT01065454 ↗ | A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction | Active, not recruiting | Bayer | Phase 2 | 2010-04-14 | The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction |
NCT01165931 ↗ | Coronary Vasomotor Response After Riociguat Exposure | Withdrawn | Bayer | Phase 2 | 2012-05-01 | The aim of the study is to assess the effects of intracoronary Riociguat on coronary blood flow in subjects with coronary artery disease and to compare this effect with the intracoronary nitroglycerin, a coronary vasodilator widly used to treat patients with coronary artery disease. |
NCT01172756 ↗ | A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction | Terminated | Bayer | Phase 2 | 2010-07-01 | The aim of this study is to assess whether single oral doses of Riociguat safely improve the cardiovascular function in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction |
NCT01179334 ↗ | Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters. | Completed | Bayer | Phase 2 | 2010-08-01 | Pulmonary Arterial Hypertension (PAH) is a severe progressive disease with a high mortality. Although several drugs are available for the treatment of PAH none offer a cure, therefore there is still a high medical need for new treatments. Soluble guanylate cyclase (sGC) is one of the chemicals involved in the pathways controlling vascular tone, which is impaired in patients with PAH. This causes constriction and thickening of the blood vessels wall in the lungs and increase of blood pressure in the lungs. This can lead to the very debilitating symptoms of PAH such as tiredness, shortness of breath on exertion, collapse and often the inability of the patient to perform their daily life activities. Inhalation of Nitric Oxide, which activates sGC is used to treat PAH, but its effect wears off as soon as inhalation stops. Direct stimulation of sGC using this new compound Riociguat may be a new approach for the treatment of PAH. The phosphodiesterase 5 (PDE5)-inhibitor Sildenafil is one of licensed treatments for PAH. The Patent Plus is a double-blind, placebo-controlled safety study, designed to investigate the effect of Riociguat on blood pressure in patients with PAH when given in combination with Sildenafil. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RIOCIGUAT
Condition Name
Clinical Trial Locations for RIOCIGUAT
Trials by Country
Clinical Trial Progress for RIOCIGUAT
Clinical Trial Phase
Clinical Trial Sponsors for RIOCIGUAT
Sponsor Name